Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

Roche Holdings AG said it will begin a late-stage trial to evaluate whether its experimental Alzheimer’s drug, trontinemab, ...

In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months of treatment, representing what B. Riley Securities called a “paradigm shift ...

After three years on Leqembi, 59% of people with no or very low tau levels did not see their Alzheimer's progress at all, according to the presentation. A little over half of that patient ...

Because Leqembi is a Part B drug, not a more common Part D drug, many Medicare patients will owe 20 percent of the cost out-of-pocket. That adds up to more than $5,000 annually.

Leqembi is the second anti-amyloid drug to hit the market, but its predecessor was the controversial Aduhelm. The FDA granted accelerated approval to Aduhelm in 2021, despite a recommendation from ...

The US Food and Drug Administration on Thursday granted traditional full approval to the Alzheimer’s drug Leqembi, the first medicine proven to slow the course of the memory-robbing disease. The ...

Leqembi, a drug that can help treat adult patients with Alzheimer’s, was given traditional approval by the FDA on Thursday. It was first approved in January for clinical trials.

Leqembi targets the amyloid protein that builds up in the form of plaques in the brains of people with Alzheimer's disease, said Dr. Judith Heidebrink, a neurologist at Michigan Medicine and ...

Alzheimer's drug Leqembi – a treatment proven to slow the clinical aspects of the progressive disease – could soon be available at several major U.S. health care systems. The Food and Drug ...

A treatment for Alzheimer’s disease is on its way to many more patients across the U.S. The Food and Drug Administration on Thursday granted full approval to Leqembi, allowing Medicare enrollees ...

Eisai says it will sell Leqembi for an average of $26,500 per year. The independent non-profit Institute for Clinical and Economic Review calculates a cost-effective annual price for a typical ...